Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical trials of agents that reverse multidrug-resistance.

× No keyword cloud information.

17 in total

Review 1. Drug resistance in oncology: from concepts to applications.

Authors: J L Cazin; P Gosselin; P Cappelaere; J Robert; A Demaille
Journal: J Cancer Res Clin Oncol Date: 1992 Impact factor: 4.553

Review 2. Genetic basis of multidrug resistance of tumor cells.

Authors: S E Kane; I Pastan; M M Gottesman
Journal: J Bioenerg Biomembr Date: 1990-08 Impact factor: 2.945

Review 3. Rationale for immunotherapy of renal cell carcinoma.

Authors: R Heicappell; R Ackermann
Journal: Urol Res Date: 1990

4. Effect of dose and dosage interval on the oral bioavailability of docetaxel in combination with a curcumin self-emulsifying drug delivery system (SEDDS).

Authors: Yi-Dong Yan; Nirmal Marasini; Young Keun Choi; Jong Oh Kim; Jong Soo Woo; Chul Soon Yong; Han Gon Choi
Journal: Eur J Drug Metab Pharmacokinet Date: 2011-12-27 Impact factor: 2.441

5. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance.

Authors: G H Mickisch; G T Merlino; H Galski; M M Gottesman; I Pastan
Journal: Proc Natl Acad Sci U S A Date: 1991-01-15 Impact factor: 11.205

6. Differential effectiveness of a range of novel drug-resistance modulators, relative to verapamil, in influencing vinblastine or teniposide cytotoxicity in human lymphoblastoid CCRF-CEM sublines expressing classic or atypical multidrug resistance.

Authors: B T Hill; L K Hosking
Journal: Cancer Chemother Pharmacol Date: 1994 Impact factor: 3.333

7. Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours.

Authors: T W Beer; D C Rowlands; J Crocker
Journal: Thorax Date: 1996-05 Impact factor: 9.139

8. Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells.

Authors: V Wiebe; S Koester; M Lindberg; V Emshoff; J Baker; G Wurz; M DeGregorio
Journal: Invest New Drugs Date: 1992-07 Impact factor: 3.850

9. Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study.

Authors: Saroj Niraula; Greg Pond; Ronald de Wit; Mario Eisenberger; Ian F Tannock; Anthony M Joshua
Journal: Can Urol Assoc J Date: 2013 Jan-Feb Impact factor: 1.862

10. Targeting chemosensitizing doses of toremifene based on protein binding.

Authors: G T Wurz; V D Emshoff; M W DeGregorio; V J Wiebe
Journal: Cancer Chemother Pharmacol Date: 1993 Impact factor: 3.333